November 18, 2019
Boston, Massachusetts USA
Founded by Dr. Bruce A. Chabner, this annual symposium, presented in joint partnership with the Massachusetts General Hospital Cancer Center, encourages dialogue among experts on topics that bring cancer biology to clinical application. The Chabner Colloquium is an intensive and thoughtful look at the potential for rational, collaborative drug development, tapping into the resources of government, pharmaceutical and biotech companies, and globally statured cancer centers of excellence.
Focusing on new targets and their interventions; strategies for profiling and selection of patients
for targeted drug trials; and biomarkers and animal models to guide clinical development, the entire drug development process is represented. The Chabner Colloquium provides a dialogue that influences trial design, hastens cancer drug development, and, long-term, will rationalize and lend efficiency to the practice of oncology.
New Insights into DNA Repair and Drug Response
Targeting the ATR Kinase in Cancer Therapy
PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
Assessing DNA Repair in Clinical Trials
Targets That Defy Effective Therapy
Developing Therapies for Ras-driven Cancers
Is FGFR Inhibition an Effective Target in Gastrointestinal Tumors?
Intergenic Fusions in Advanced HR+ Breast Cancer
Promising Drug-antibody Conjugates and Cell Death Pathway Inhibitors
Genomic and Functional Characterization of Patient Derived Xenograft Models of Small Cell Lung Cancer
Antibody Drug Conjugates for Triple Negative Breast Cancer: Targeting Positive in the Negative
PARP in Breast Cancer
Junior Faculty Forum
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Financial Toxicity of Cancer
Improving Therapy for EGFR-Mutant Lung Cancers